What Is Drug Substance Manufacturing and Why Is It Critical in Pharma?

Drug substance manufacturing refers to the production of the active pharmaceutical ingredient (API) – the core component of a medicine that provides its therapeutic effect.

It is critical in pharma because the API is the foundation of any drug – without a high-quality drug substance, you cannot have a safe or effective medicine.

The drug substance’s quality, consistency, and availability directly impact a drug’s efficacy and patient safety, making its manufacturing one of the most crucial components of the pharmaceutical supply chain.

Drug Substance vs. Drug Product: Understanding the Difference

It’s important to differentiate drug substances from drug products. A drug substance is the chemically active component intended to produce a therapeutic effect. It is typically manufactured through complex chemical synthesis, isolation from natural sources, or biotechnological processes.

In contrast, a drug product is the finished form of the medication that patients use – for example, a pill, capsule, injectable vial, cream, etc.

Different regulations and guidelines apply to each; for instance, stability testing and specifications are defined separately for the API manufacturing process versus the final product.

Recognizing the difference helps pharmaceutical teams ensure each stage – making the API and formulating the final medicine – gets the specialized attention and controls it requires.

Where Drug Substance Manufacturing Fits in Pharma Stages

Pharmaceutical manufacturing stages involve drug substance manufacturing as the first critical stage. An end-to-end drug production process usually consists of three main steps: Drug Substance, Drug Product, and Finished Good (packaging).

• The drug substance stage comes first – this is when the API is produced (often starting from raw materials or precursor chemicals).
• Only once the API is made do manufacturers move on to the drug product stage, where the API is formulated into a dosage form (e.g., pressing it into tablets or filling it into capsules with excipients).
• Finally, the finished product stage involves packaging and labeling the formulated drug product for distribution. 

The Step-by-Step Drug Substance Process Development

Drug substance manufacturing is typically a multi-step process that transforms starting materials into the final active ingredient. While specific processes vary by molecule, there are some common stages in API production:

• Reaction & Synthesis: The process usually begins with one or more chemical reactions (or biotech production steps) to create the target molecule. Raw materials or intermediates are converted into the desired compound through organic synthesis or other methods.
• Purification: Once the desired compound is generated, it must be purified. The crude reaction mixture often contains impurities, side-products, residual solvents, or unreacted materials. Purification steps (filtration, crystallization, chromatography, etc.) play a critical role in removing impurities and isolating the API in a pure form.
• Isolation & Drying: After purification, the API is typically isolated as a solid. For small molecule API manufacturing, this often involves crystallizing the API out of solution and filtering or centrifuging to collect the solid product. The API solids are then dried to achieve a stable form.

Throughout this manufacturing process, maintaining control over critical process parameters and critical quality attributes is vital. Every step is carefully designed and validated during process development to ensure it can consistently produce an API that meets predefined quality specifications.

Equally important in API manufacturing is the development work that precedes large-scale production. Process development involves finding the optimal synthetic route and reaction conditions to produce the drug substance efficiently and safely.

Route scouting and process optimization are conducted to choose the best chemistry for scale-up, aiming for high yield and purity while minimizing steps and cost.

Why Drug Substance Manufacturing Is So Critical

Drug substance manufacturing is critical to the pharmaceutical industry’s success because it directly impacts a drug’s quality, safety, efficacy, and availability.

The API is often called the “heart” of a medicine – it’s the ingredient that actually provides the treatment. If the drug substance is not right, the final medicine cannot be effective. Here are a few key reasons this stage is so critical:

• Therapeutic Efficacy and Safety: The drug substance dictates the pharmacological activity of the drug. It must be made to exacting purity and potency standards. Any variation or impurity in the API can alter how the drug works or introduce toxic effects. Ensuring the API is high quality and consistent batch-to-batch is paramount for patient safety.
• Foundation for Drug Development: In the drug development process, once a lead compound is identified in research, producing sufficient quantities of that API for toxicology studies, clinical trials, and ultimately commercial use is a major challenge. The timelines of clinical trials and new drug launches often hinge on how quickly and reliably the drug substance can be made. Any delays or failures in API production can halt a drug substance development.
• Quality and Compliance: Drug substance manufacturing is highly regulated. Companies must ensure their API meets all quality requirements before it is formulated into a drug product. Only if the API passes all specifications can it move forward. By building quality into the manufacturing process via Good Manufacturing Practices and quality-by-design principles, manufacturers prevent issues rather than fixing them later. GMP drug substance manufacturing underpins the overall quality assurance of pharmaceuticals.
• Supply Chain Reliability: The drug substance often represents the first link in the medicine supply chain. Many pharmaceutical companies source APIs from specialized manufacturers or their own facilities; if that supply is disrupted, drug product manufacturing cannot continue, leading to potential drug shortages. We have seen examples where the inability to get the API halted production of essential medicines. 

The Role of CDMOs in Drug Substance Manufacturing

Considering the complexity and importance of drug substance manufacturing, many pharmaceutical companies rely on specialized partners to carry out this stage.

Contract Development and Manufacturing Organizations (CDMOs) provide services to develop and manufacture drug substances (and often drug products).

What is a CDMO for pharma companies? Leveraging pharmaceutical CDMO services allows companies to tap into an existing infrastructure of expertise, facilities, and regulatory know-how, rather than building those capabilities in-house.

This has become increasingly common as pharma companies are turning to external partners who already have the expertise and regulatory knowledge to bring drugs to market faster and more efficiently.

Neuland Labs’ Expertise in Drug Substance Manufacturing

Neuland is a pure-play API manufacturer with over 40 years of expertise (established in 1984) focused on developing and producing complex small-molecule and peptide drug substances.

Over the decades, Neuland has served 500+ customer projects across more than 80 countries. As a result, Neuland has built a strong track record in reliably delivering high-quality drug substances at various scales.

Neuland Labs prides itself on a broad range of capabilities and achievements in API manufacturing:

• Peptide Manufacturing Specialization: In addition to small molecules, Neuland is a recognized leader in peptide drug substance manufacturing – a niche that requires specialized techniques. We utilize solid-phase peptide synthesis (SPPS) for rapid, automated assembly of peptide chains, as well as solution-phase and hybrid synthesis strategies for larger or more complex peptides.
• Regulatory Compliance and Global Certifications: Neuland Labs’ facilities operate under strict cGMP and have been audited and approved by major regulatory agencies worldwide. Certifications held by Neuland include those from the US FDA, EMA (Europe), PMDA (Japan), and many other regulatory bodies.
• End-to-End CDMO Services: Neuland offers an end-to-end solution for drug substance development. We assist clients with early-stage process development, utilizing their R&D center to develop and optimize synthetic routes. We then provide scale-up and manufacturing in phase-appropriate facilities – from non-GMP pilot batches to full cGMP commercial production. 

Neuland’s long history and specialized focus on APIs have resulted in numerous successful projects, including complex generics and custom novel APIs. Connect with us today to bring your drug substance to life.